Posted: 30 October 2024
BioMelbourne Network, Victoria’s leading industry association for organisations engaged in biotechnology, medical technology, and health innovation in Victoria and AusBiotech, Australia’s leading national industry association representing more than 3000 members across the life sciences sector, have announced the signing of a Memorandum of Understanding (MOU) to promote stronger collaboration between both organisations.
The MOU marks a significant milestone as the organisations work to support the state and national growth agenda for the life sciences ecosystem. It recognises the opportunity that greater industry collaboration offers, as a key to unlocking the sector’s full potential.
Under the terms of the MOU, BioMelbourne Network and AusBiotech will further their collaboration across the key areas of member connection, knowledge sharing and sector advocacy.
Karen Parr, CEO of BioMelbourne Network, commented:
“This MOU represents more than just an agreement; it’s a commitment between BioMelbourne Network and AusBiotech for greater collaboration as we drive a shared vision for our sector’s healthy and robust future.”
“As the voice of Victoria’s growing and thriving healthtech sector, it’s critical that the depth of experience present in this state supports the national discussion, and that vice versa, so that together we create new opportunities and insights that strengthens the innovation present.
“Our organisations are dedicated to advocating for our members and a united industry will elevate and build a sector who benefits from our shared success.”
Rebekah Cassidy, CEO of AusBiotech, said:
“I couldn’t be more delighted to formalise AusBiotech’s relationship with BioMelbourne Network. Both of our organisations have a proud history of advocating on behalf of our members and share common goals when it comes to furthering the opportunities for life sciences sector growth.
“The combined pressures of a changing world, including pandemics, supply chain stress, aging populations, climate change and geopolitical tension mean that Australia’s capacity to strategically build on its health and medical research strengths, by growing and retaining a thriving commercialised biotech and medtech sector, has never been more important.
These factors bring into sharp focus the need for all parts of our industry to collaborate and build cohesive voice that furthers Australia’s on shore biotechnology development and commercialisation capability. The signing of this MOU is an important step toward that.
